Diagnostic Kits/Patents and the Progress of Personalized Medicine: Difference between revisions
Jump to navigation
Jump to search
AClearwater (talk | contribs) (New page: Herder, M., Patents & the Progress of Personalized Medicine: Biomarkers Research as Lens. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1435468 [Accessed ...) |
AClearwater (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
#Therapeutic biomarkers: "provide a quantifiable measure of response to therapy in patients undergoing treatment." (Wilson et al., 2007) | #Therapeutic biomarkers: "provide a quantifiable measure of response to therapy in patients undergoing treatment." (Wilson et al., 2007) | ||
#Toxicity biomarkers: "biomarkers can be used to identify patients at risk for developing adverse reactions to individual therapeutics." (Wilson et al., 2007) | #Toxicity biomarkers: "biomarkers can be used to identify patients at risk for developing adverse reactions to individual therapeutics." (Wilson et al., 2007) | ||
Types of "genetic testing" services | |||
#Diagnostics: "companies can go to market as soon as they have phenotype-gene association information and the necessary | |||
genetic sequencing equipment in hand. (Herder, M., 2009) | |||
#Pharmacogenomics(also pharmacogenetics): personalized medicine through incorporate genetic information into drug choice | |||
#Theragnostics: focuses on "integration of information from a diverse set of biomarkers" (Herder, M., 2009) | |||
Revision as of 11:21, 2 October 2009
Herder, M., Patents & the Progress of Personalized Medicine: Biomarkers Research as Lens. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1435468 [Accessed October 1, 2009].
A. Biology, Language, & Markets types of biomarkers:
- Diagnostic biomarkers: "identify the presence of disease at the earliest stage, before clinical manifestation. (Wilson et al., 2007)
- Prognostic biomarkers "stratify risk of disease progression in patients undergoing definitive therapy." (Wilson et al., 2007)
- Predictive biomarkers: identify patients most likely to respond to specific interventions." (Wilson et al., 2007)
- Therapeutic biomarkers: "provide a quantifiable measure of response to therapy in patients undergoing treatment." (Wilson et al., 2007)
- Toxicity biomarkers: "biomarkers can be used to identify patients at risk for developing adverse reactions to individual therapeutics." (Wilson et al., 2007)
Types of "genetic testing" services
- Diagnostics: "companies can go to market as soon as they have phenotype-gene association information and the necessary
genetic sequencing equipment in hand. (Herder, M., 2009)
- Pharmacogenomics(also pharmacogenetics): personalized medicine through incorporate genetic information into drug choice
- Theragnostics: focuses on "integration of information from a diverse set of biomarkers" (Herder, M., 2009)